Discovery and Background
BPC-157 was first isolated and characterized by researchers at the University of Zagreb, Croatia, led by Dr. Predrag Sikiric. The compound is a 15-amino acid fragment (GEPPPGKPADDAGLV) derived from human Body Protection Compound (BPC), a protein found in gastric juice. Initial research focused on its gastroprotective properties, but subsequent studies revealed a remarkably broad spectrum of tissue-protective and regenerative effects across multiple organ systems. The compound has been studied in over 100 published preclinical studies, making it one of the most comprehensively characterized research peptides available.
Mechanism of Action
BPC-157 exerts its effects through multiple molecular pathways. It upregulates vascular endothelial growth factor receptor 2 (VEGFR2) and fibroblast growth factor receptor (FGFR), promoting angiogenesis and tissue vascularization. It activates the FAK-paxillin pathway, which is critical for cell migration and wound healing. BPC-157 also modulates the nitric oxide (NO) system, with both NO-dependent and NO-independent mechanisms described in the literature. Additionally, it interacts with the growth hormone receptor and has been shown to upregulate EGR-1 (early growth response protein 1), a transcription factor involved in tissue repair gene expression. This multi-pathway mechanism may explain BPC-157's broad efficacy across diverse tissue types.
Key Research Areas
The published research on BPC-157 spans several major areas. In musculoskeletal research, studies have demonstrated accelerated healing of tendons, ligaments, and muscles in rodent models of injury. In gastrointestinal research, BPC-157 has shown protective effects against NSAID-induced ulcers, inflammatory bowel disease models, and intestinal fistulas. Neurological research has explored BPC-157's potential in traumatic brain injury models, spinal cord injury, and dopaminergic system modulation. Cardiovascular studies have investigated its effects on heart failure models and vascular injury. The compound's stability in gastric acid (unlike most peptides) has made it a subject of interest for oral delivery research.
Research Considerations
Despite extensive preclinical data, BPC-157 has not yet progressed to large-scale Phase 3 clinical trials in Western medicine, though some early-phase human studies have been conducted. Researchers should note that the vast majority of published data comes from rodent models, and translation to human physiology requires careful consideration. Purity and quality of the research compound are critical variables — studies consistently use ≥98% HPLC-verified material. The compound is typically studied as a lyophilized powder reconstituted in bacteriostatic water or saline. Researchers should source from suppliers providing ISO 17025-verified certificates of analysis.
Quality documentation toolkit
Continue your COA review
Use the same repeatable documentation checks across every research peptide review. COA Check organizes visible document fields; laboratory verification remains the route for authenticity confirmation.